Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis

Summary

DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH DERMATOMYOSITIS

Timeline

Start

2018-08-02

Primary completion

2018-11-22

Completion

2018-11-29

Outcome

Outcome not reported

Stopped (Enrollment): “Study complexity, low study recruitment”

Drugs

Indications